Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LeonaBio, Inc.LONA · Entity 1487 | Director | June 23, 2026 | June 24, 2026 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director · CHIEF EXECUTIVE OFFICER | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LeonaBio, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2036-06-22 | Direct | 28,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 28,000 · Balance 28,000 F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Vaxcyte, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 429,902 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Tax withholding · Disposed 17,056 · Balance 429,902 F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 133,215 F2: Shares are held directly by a trust for the benefit of the Reporting Person's son. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 133,215 F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F2: Shares are held directly by a trust for the benefit of the Reporting Person's son.
F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2022 Filed May 18, 2022 20:39 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 11,000 | $1.79 | $19,690.00 |
DisclosureSEC source: 0001209191-22-030067 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:54 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-22-025010 · doc4.xml · derivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,450 Underlying: Common Stock · 11,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:54 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 11,000 | $23.98 | $263,765.70 |
DisclosureSEC source: 0001209191-22-025010 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,894 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $23.79 to $24.49. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 20:54 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 11,000 | $1.79 | $19,690.00 |
DisclosureSEC source: 0001209191-22-025010 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 22:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 7,712 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-22-020815 · doc4.xml · derivative · entry 8 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,450 Underlying: Common Stock · 7,712 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 22:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,712 | $24.62 | $189,861.73 |
DisclosureSEC source: 0001209191-22-020815 · doc4.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,894 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.20 to $25.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 22:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 7,712 | $1.79 | $13,804.48 |
DisclosureSEC source: 0001209191-22-020815 · doc4.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 711,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 22:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 14,288 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-22-020815 · doc4.xml · derivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,162 Underlying: Common Stock · 14,288 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 22:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 359 | $25.68 | $9,220.27 |
DisclosureSEC source: 0001209191-22-020815 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,894 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.635 to $25.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 22:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 13,929 | $24.92 | $347,060.54 |
DisclosureSEC source: 0001209191-22-020815 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704,253 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.55 to $25.48. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 22:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 14,288 | $1.79 | $25,575.52 |
DisclosureSEC source: 0001209191-22-020815 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 01:50 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 431,250 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001209191-22-016520 · doc4.xml · derivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,250 Underlying: Common Stock · 431,250 shares Expires 2032-03-01 F2 · derivative.exercise_date: 1/48 of shares subject to the option vest on April 2, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 01:50 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 71,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016520 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,894 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2022 and 12.5% of the shares every six months thereafter. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:04 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 27,742 | $0.00 Strike: $9.91 | $0.00 |
DisclosureSEC source: 0001209191-22-005622 · doc4.xml · derivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,742 Underlying: Common Stock · 27,742 shares Expires 2032-01-26 F1 · derivative.exercise_date: One thirty-sixth of the shares subject to the option will vest on February 27, 2022 and one thirty-sixth of the shares subject to the option will vest each month thereafter. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 1,400 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-21-071375 · doc4.xml · derivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,332 Underlying: Common Stock · 1,400 shares Expires 2028-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on July 24, 2019, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 50,365 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-071375 · doc4.xml · derivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,450 Underlying: Common Stock · 50,365 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 1,400 | $2.03 | $2,842.00 |
DisclosureSEC source: 0001209191-21-071375 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 50,365 | $1.79 | $90,153.35 |
DisclosureSEC source: 0001209191-21-071375 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 22:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-066539 · doc4.xml · derivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,815 Underlying: Common Stock · 15,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 22:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,890 | $24.00 | $141,360.00 |
DisclosureSEC source: 0001209191-21-066539 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $23.60 to $24.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 22:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 9,110 | $23.09 | $210,349.90 |
DisclosureSEC source: 0001209191-21-066539 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586,144 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.58 to $23.54. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 22:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $1.79 | $26,850.00 |
DisclosureSEC source: 0001209191-21-066539 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 20:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-061373 · doc4.xml · derivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,815 Underlying: Common Stock · 15,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 20:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,009 | $23.19 | $23,398.71 |
DisclosureSEC source: 0001209191-21-061373 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $23.13 to $23.24. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 20:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 13,991 | $22.54 | $315,357.14 |
DisclosureSEC source: 0001209191-21-061373 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 581,263 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.10 to $23.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 20:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $1.79 | $26,850.00 |
DisclosureSEC source: 0001209191-21-061373 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2021 Filed Sep 23, 2021 21:40 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 4,193 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-057469 · doc4.xml · derivative · entry 8 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,815 Underlying: Common Stock · 4,193 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| September 22, 2021 Filed Sep 23, 2021 21:40 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,193 | $25.19 | $105,635.51 |
DisclosureSEC source: 0001209191-21-057469 · doc4.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.90 to $25.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 22, 2021 Filed Sep 23, 2021 21:40 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 4,193 | $1.79 | $7,505.47 |
DisclosureSEC source: 0001209191-21-057469 · doc4.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 21:40 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 10,807 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-057469 · doc4.xml · derivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,008 Underlying: Common Stock · 10,807 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 21:40 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 802 | $25.89 | $20,763.78 |
DisclosureSEC source: 0001209191-21-057469 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.88 to $25.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 21:40 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 10,005 | $25.17 | $251,825.85 |
DisclosureSEC source: 0001209191-21-057469 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 581,056 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.73 to $25.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 21:40 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 10,807 | $1.79 | $19,344.53 |
DisclosureSEC source: 0001209191-21-057469 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 22:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 13,669 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-053357 · doc4.xml · derivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,815 Underlying: Common Stock · 13,669 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 22:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 69 | $23.10 | $1,593.90 |
DisclosureSEC source: 0001209191-21-053357 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 22:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 13,600 | $22.73 | $309,128.00 |
DisclosureSEC source: 0001209191-21-053357 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,323 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.00 to $22.985. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 22:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 13,669 | $1.79 | $24,467.51 |
DisclosureSEC source: 0001209191-21-053357 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 1,331 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-052762 · doc4.xml · derivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,484 Underlying: Common Stock · 1,331 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,331 | $22.40 | $29,809.87 |
DisclosureSEC source: 0001209191-21-052762 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.135 to $22.62. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 1,331 | $1.79 | $2,382.49 |
DisclosureSEC source: 0001209191-21-052762 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 581,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 20:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-047779 · doc4.xml · derivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,815 Underlying: Common Stock · 15,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 20:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 15,000 | $22.85 | $342,685.50 |
DisclosureSEC source: 0001209191-21-047779 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.20 to $23.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 20:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $1.79 | $26,850.00 |
DisclosureSEC source: 0001209191-21-047779 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 21:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 13,863 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-043502 · doc4.xml · derivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,815 Underlying: Common Stock · 13,863 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 21:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 6,576 | $23.36 | $153,615.36 |
DisclosureSEC source: 0001209191-21-043502 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $23.24 to $23.62. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 21:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,287 | $22.85 | $166,507.95 |
DisclosureSEC source: 0001209191-21-043502 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586,830 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.22 to $23.21. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 21:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 13,863 | $1.79 | $24,814.77 |
DisclosureSEC source: 0001209191-21-043502 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 74 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-042764 · doc4.xml · derivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,678 Underlying: Common Stock · 74 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 74 | $22.00 | $1,628.00 |
DisclosureSEC source: 0001209191-21-042764 · doc4.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,254 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 74 | $1.79 | $132.46 |
DisclosureSEC source: 0001209191-21-042764 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.